Search alternatives:
significant potential » significant positive (Expand Search)
potential decrease » substantial decrease (Expand Search)
barrier decrease » barrier disease (Expand Search), marked decrease (Expand Search), barrier creates (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 81 - 100 results of 25,246 for search '(( significant ((barrier decrease) OR (larger decrease)) ) OR ( significant potential decrease ))', query time: 0.57s Refine Results
  1. 81
    Decreased expression of tight junction proteins and disruption of intestinal barrier integrity in DSS-induced colitis mouse model.

    Decreased expression of tight junction proteins and disruption of intestinal barrier integrity in DSS-induced colitis mouse model. by Mariam Wed Eladham (21439745)

    Published 2025
    Save to List
    Saved in:
  2. 82
    Significantly Enriched Pathways.

    Significantly Enriched Pathways. by Jiyong Zhang (2498740)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 83
    Statins resulted in smaller neuronal soma size.

    Statins resulted in smaller neuronal soma size. by Shuk C. Tsoi (21192243)

    Published 2025
    “…Statin treatment decreased cell sizes in the larger cells more than in the smaller cells as seen in the greater divergence between lines plotted for larger cell somas (bottom panel). …”
    Save to List
    Saved in:
  4. 84
    <i>Lp</i> knockdown significantly impairs oogenesis and affects Vg localization.

    <i>Lp</i> knockdown significantly impairs oogenesis and affects Vg localization. by Iryna Stryapunina (17867390)

    Published 2024
    Save to List
    Saved in:
  5. 85
    Ordination of butterfly community composition change through time.

    Ordination of butterfly community composition change through time. by Nicole B. Kucherov (11558817)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  6. 86
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 87
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 88
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 89
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 90
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 91
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 92
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 93
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 94
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 95
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 96
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 97
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 98
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 99
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 100
    Phase 2 significant effects.

    Phase 2 significant effects. by Wendy C. Crone (2262169)

    Published 2023
    Save to List
    Saved in:

Search Tools: